Cytokine Profiles in Autoantibody Defined Subgroups of Systemic Lupus Erythematosus.
Frida TorellSusanna EketjällHelena IdborgPer-Johan JakobssonIva GunnarssonElisabet SvenungssonJohan TryggPublished in: Journal of proteome research (2019)
The aim of this study was to evaluate how the cytokine profiles differed between autoantibody based subgroups of systemic lupus erythematosus (SLE). SLE is a systemic autoimmune disease, characterized by periods of flares (active disease) and remission (inactive disease). The disease can affect many organ systems, e.g., skin, joints, kidneys, heart, and the central nervous system (CNS). SLE patients often have an overproduction of cytokines, e.g., interferons, chemokines, and interleukins. The high cytokine levels are part of the systemic inflammation, which can lead to tissue injury. In the present study, SLE patients were divided into five groups based on their autoantibody profiles. We thus defined these five groups: ANA negative, antiphospholipid (aPL) positive, anti-Sm/anti-RNP positive, Sjögren's syndrome (SS) antigen A and B positive, and patients positive for more than one type of autoantibodies (other SLE). Cytokines were measured using Mesoscale Discovery (MSD) multiplex analysis. On the basis of the cytokine data, ANA negative patients were the most deviating subgroup, with lower levels of interferon (IFN)-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-12/IL-23p40, and interferon gamma-induced protein (IP)-10. Despite low cytokine levels in the ANA negative group, autoantibody profiles did not discriminate between different cytokine patterns.
Keyphrases
- systemic lupus erythematosus
- end stage renal disease
- disease activity
- ejection fraction
- newly diagnosed
- chronic kidney disease
- rheumatoid arthritis
- peritoneal dialysis
- heart failure
- clinical trial
- multiple sclerosis
- machine learning
- small molecule
- blood brain barrier
- atrial fibrillation
- big data
- artificial intelligence
- phase iii
- single cell
- patient reported
- diabetic rats
- high glucose